Annuity Payments For Costly One-Off Drugs Are No Magic Bullet
Executive Summary
Paying for expensive one-off treatments in installments rather than one lump sum could be appropriate for some products, but fails to address wider systemic problems.
You may also be interested in...
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: